Generex Biotechnology Corporation
GNBTQ
OTC PK
| Weiss Ratings | GNBTQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | -- | |||
| Risk Index | -- | |||
| Risk Grade | -- | |||
| Reward Grade | -- | |||
| Rating Factors | GNBTQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | -- | |||
| Efficiency Index | -- | |||
| Solvency Index | -- | |||
| Total Return Index | -- | |||
| Volatility Index | -- | |||
| Beta / Standard Deviation | GNBTQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 69.22 | |||
| Price History | GNBTQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -- | |||
| 30-Day Total Return | -- | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | -- | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -99.00% | |||
| 3-Year Total Return | -100.00% | |||
| 5-Year Total Return | -100.00% | |||
| 52-Week High % Change | 0.00% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | GNBTQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Nov 20, 2024 | |||
| 52-Week High Price (Date) | Nov 20, 2024 | |||
| Valuation | GNBTQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | -- | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | 0.00 | |||
| Earnings Per Share (TTM) | -0.52 | |||
| Earnings Per Share Growth | 24.06% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.00 | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | -- | |||
| Dividends and Shares | GNBTQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 140.41M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | GNBTQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 416 364 2551 | |||
| Address | 10102 USA Today Way Miramar, FL 33025 | |||
| Website | generex.com/index.html | |||
| Country | United States | |||
| Year Founded | 1983 | |||
| Profitability | GNBTQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -4,952.93% | |||
| Profit Margin | -5,379.21% | |||
| Management Effectiveness | GNBTQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -43.84% | |||
| Return on Equity | -- | |||
| Income Statement | GNBTQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 692.70K | |||
| Total Revenue (TTM) | 692.70K | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | 334.10K | |||
| EBITDA (TTM) | -33.30M | |||
| EBIT (TTM) | -34.31M | |||
| Net Income (TTM) | -37.26M | |||
| Net Income Avl. to Common (TTM) | -37.26M | |||
| Total Revenue Growth (Q YOY) | -95.85% | |||
| Earnings Growth (Q YOY) | 247.29% | |||
| EPS Diluted (TTM) | -0.52 | |||
| EPS Diluted Growth (Q YOY) | 40.22% | |||
| Balance Sheet | GNBTQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.68M | |||
| Cash Per Share (Q) | $0.01 | |||
| Total Current Assets (Q) | 2.47M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -44.08M | |||
| Current Ratio (Q) | 0.039 | |||
| Book Value Per Share (Q) | -$0.48 | |||
| Total Assets (Q) | 45.92M | |||
| Total Current Liabilities (Q) | 64.07M | |||
| Total Debt (Q) | 10.60M | |||
| Total Liabilities (Q) | 90.01M | |||
| Total Common Equity (Q) | -56.33M | |||
| Cash Flow | GNBTQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 0.00 | |||
| Cash from Financing (TTM) | 3.64M | |||
| Net Change in Cash (TTM) | 1.26M | |||
| Levered Free Cash Flow (TTM) | 9.57M | |||
| Cash from Operations (TTM) | -2.37M | |||
